U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Accession: PRJNA742032 ID: 742032

Perturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs

This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series
AccessionPRJNA742032; GEO: GSE179064
TypeUmbrella project
PublicationsCarraro C et al., "Decoding mechanism of action and sensitivity to drug candidates from integrated transcriptome and chromatin state.", Elife, 2022 Aug 31;11
SubmissionRegistration date: 28-Jun-2021
Genomics and Immunoregulation, LIMES (Life and Medical Sciences Center Genomics and Immunoregulation)
RelevanceSuperseries
Project Data:
Resource NameNumber
of Links
Sequence data
SRA Experiments60
Publications
PubMed1
PMC1
Other datasets
BioSample60
GEO DataSets3
GEO Data Details
ParameterValue
Data volume, Supplementary Mbytes7
SRA Data Details
ParameterValue
Data volume, Gbases399
Data volume, Tbytes0.15
Perturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs encompasses the following 2 sub-projects:
Project TypeNumber of Projects
Epigenomics1
BioProject
accession
OrganismTitle
PRJNA742038Homo sapiensPerturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs [ATAC-Seq] (Genomics and Immunoregulation,...)
Transcriptome or Gene expression1
BioProject
accession
OrganismTitle
PRJNA742031Homo sapiensPerturbation-informed signatures from crosswise integration of transcriptome and chromatin accessibility analyses predict susceptibility to candidate anticancer drugs [RNA-Seq] (Genomics and Immunoregulation,...)

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center